KNSA — Kiniksa Pharmaceuticals International, plc Stock Price, Chart & AI Report

Positive Jul 28, 2026 • 11:30 UTC GlobeNewswire Inc. • Na

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals reported Q2 2026 net product revenue of $243.6 million for ARCALYST, representing 55% year-over-year growth, and raised full-year 2026 guidance to $980-995 million. The company announced positive Phase 2 data for KPL-387 showing rapid pain and inflammation reduction, with the pivotal Phase 3 PASTORALE trial now enrolling patients. KPL-1161 development is on track for Phase 1 initiation by end of 2026. The company maintains a strong balance sheet with $525.9 million in cash and no debt.

KNSA ARCALYST KPL-387 KPL-1161 recurrent pericarditis IL-1 pathway inhibition Phase 3 trial revenue growth

Sentiment note

Strong Q2 revenue growth of 55% year-over-year, raised full-year guidance, positive Phase 2 data for lead pipeline candidate KPL-387 supporting Phase 3 initiation, solid cash position of $525.9 million with no debt, and cash flow positive operations demonstrate strong commercial execution and clinical progress.

Positive Apr 28, 2026 • 23:10 UTC The Motley Fool • Eric Volkman

Why Kiniksa Pharmaceuticals International Stock Raced Nearly 24% Higher Today

Kinikska Pharmaceuticals International (KNSA) surged nearly 24% after reporting strong Q1 2026 earnings that beat analyst expectations. Revenue from its drug Arcalyst reached $214 million (vs. $138 million year-ago), and net income more than doubled to $22.6 million. The company raised its full-year Arcalyst sales guidance to $930-945 million, driven by recent approval for heart disorder pericarditis.

KNSA biotech earnings beat Arcalyst pericarditis approval revenue growth guidance raise stock surge

Sentiment note

Company delivered a beat-and-raise quarter with revenue significantly exceeding expectations ($214M vs. $207M consensus), net income more than doubling, and management raising full-year guidance. The recent pericarditis approval for Arcalyst is driving strong sales growth, and the analyst views the company's prospects as bullish despite being a single-product company.

Positive Oct 17, 2025 • 12:00 UTC GlobeNewswire Inc. • Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis

Kiniksa Pharmaceuticals received FDA Orphan Drug Designation for KPL-387, a monoclonal antibody targeting pericarditis treatment, with potential for monthly subcutaneous self-injection.

KNSA orphan drug pericarditis monoclonal antibody FDA IL-1R1

Sentiment note

Company received FDA Orphan Drug Designation, indicating promising progress in developing a novel treatment for a rare disease

Positive Jun 5, 2025 • 11:00 UTC GlobeNewswire Inc. • N/A

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis

Kiniksa Pharmaceuticals announces plans for a Phase 2/3 clinical trial of its drug KPL-387 in recurrent pericarditis, with the trial expected to initiate in mid-2025 and Phase 2 data expected in the second half of 2026.

KNSA Kiniksa Pharmaceuticals KPL-387 recurrent pericarditis clinical trial

Sentiment note

The article outlines Kiniksa's plans for a Phase 2/3 clinical trial of its drug KPL-387 in recurrent pericarditis, which suggests the company is making progress in developing a potential treatment for this condition.

Positive May 29, 2025 • 20:01 UTC GlobeNewswire Inc. • N/A

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Kiniksa Pharmaceuticals announced that country star Carly Pearce has joined their Life DisRPted campaign to raise awareness for recurrent pericarditis. The company also reported strong Q1 2025 financial results for their ARCALYST product, with net product revenue of $137.8 million and increased 2025 revenue guidance.

KNSA Kiniksa Pharmaceuticals ARCALYST recurrent pericarditis financial results

Sentiment note

The article highlights Kiniksa's successful Q1 2025 financial results for ARCALYST, with strong revenue growth and increased guidance. Additionally, the company's partnership with Carly Pearce to raise awareness for recurrent pericarditis indicates positive momentum in their business and product portfolio.

Positive Mar 14, 2025 • 09:51 UTC The Motley Fool • Keith Speights

3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now

The article highlights three healthcare stocks that are considered good investments right now: AbbVie, Vertex Pharmaceuticals, and Kiniksa Pharmaceuticals. It discusses the growth prospects and financial metrics of these companies.

ABBV VRTX KNSA healthcare stocks AbbVie Vertex Pharmaceuticals Kiniksa Pharmaceuticals

Sentiment note

Kiniksa's drug Arcalyst, approved for treating recurrent pericarditis, has seen a significant increase in sales and has a large market opportunity. The company also has a promising pipeline of other programs.

Neutral Feb 20, 2025 • 21:01 UTC GlobeNewswire Inc. • N/A

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Kiniksa Pharmaceuticals, a biopharmaceutical company, announced that it will host a conference call on February 25, 2025, to report its fourth quarter and full year 2024 financial results and recent portfolio execution.

KNSA Kiniksa Pharmaceuticals financial results portfolio execution

Sentiment note

The article provides a factual update on Kiniksa Pharmaceuticals' upcoming financial results announcement, without any explicit positive or negative sentiment.

Positive Jan 14, 2025 • 18:00 UTC GlobeNewswire Inc. • Delveinsight

Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight

The article discusses the evolving landscape of rare cardiovascular diseases, including Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy. It highlights the challenges in diagnosis and treatment, as well as the growing market size and pipeline of new therapies for these conditions.

ABBV NVS KNSA JNJ rare cardiovascular diseases Giant-Cell Arteritis Pulmonary Arterial Hypertension Restrictive Cardiomyopathy

Sentiment note

The article mentions Mavrilimumab, a pipeline therapy for Giant-Cell Arteritis, being developed by CSL/Kiniksa Pharmaceuticals, indicating their involvement in the rare disease market.

Positive Nov 4, 2024 • 18:00 UTC GlobeNewswire Inc. • Delveinsight

Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight

The urticaria pipeline is rapidly expanding, with over 20 leading companies developing 25+ new treatments to address the rising prevalence of the condition. Advances in biologic therapies and a strong R&D pipeline are driving progress, while improved healthcare infrastructure and digital innovations enhance patient access and outcomes.

REGN ALLK KNSA CLDX urticaria clinical trials pipeline biologic treatments

Sentiment note

Kiniksa Pharmaceuticals is developing the urticaria drug KPL-716, which is in clinical development.

Unknown Jun 17, 2024 • 12:30 UTC GlobeNewswire Inc. • Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis –

KNSA Health

Unknown Jun 4, 2024 • 20:01 UTC GlobeNewswire Inc. • Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference

HAMILTON, Bermuda, June 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 8:40 a.m. Eastern Time.

KNSA Calendar of Events

Unknown May 7, 2024 • 20:01 UTC GlobeNewswire Inc. • Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time).

KNSA Calendar of Events